European Archives - Page 879 of 1555 - European Medical Journal

Daiichi Sankyo's Mary Pinder-Schenck on oncology innovation

Daiichi Sankyo’s Mary Pinder-Schenck speaks about the evolution she has witnessed in oncology throughout her career and what she predicts for the future of the field.

The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance

The over-production of TNF-α can lead to chronic inflammation and organ damage in immune-mediated inflammatory diseases (IMID), such as rheumatoid arthritis (RA), axial spondyloarthritis, psoriasis, and inflammatory bowel disease (IBD). Anti-TNF therapy is generally considered to be an effective, well-tolerated treatment option for the management of chronic inflammation in these conditions.

From Clinical Trial to Real-World Evidence: Everyday Practice with METex14 Inhibitors in NSCLC

This recent hybrid satellite symposium, presented at the European Society for Medical Oncology (ESMO) 2022 Congress, addressed the current clinical practice for the management of patients with METexon14 (METex14) non-small cell lung cancer (NSCLC).

EMJ Gastroenterology 11 [Supplement 7]

This mini case study review article is the third in a series exploring tumour necrosis factor (TNF) inhibitors in the treatment of immune-mediated disease. This article explores anti-TNF therapies, which are generally considered to be an effective, well-tolerated treatment option for the management of chronic conditions related to the overproduction of TNF-α.

EMJ Diabetes 10.1 2022

The latest issue of EMJ Diabetes is now out and features an independent review of the European Association for the Study of Diabetes (EASD) Annual Meeting 2022.

EASD 2022 Abstract Highlights

The following highlights spotlight several standout abstracts presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting, covering topics such as the effects of extended overnight fasting, the incidence of congenital heart defects in the offspring of females diagnosed with pregestational diabetes, and telehealth for the metabolic control of Type 1 diabetes.

Review of the European Association for the Study of Diabetes (EASD) Annual Meeting

AFTER 2 years of virtual meetings, the 58th European Association for the Study of Diabetes (EASD) Annual Meeting took a hybrid form, with 7,716 participants onsite in Stockholm, Sweden, as well as 3,291 participants online. The programme of the congress was developed to cover the most recent developments and breaking news relating to diabetes research, covering the latest innovations and developments in the treatment of Type 1 and Type 2 diabetes (T2D), as well as their complications.

Implications of Elevated Postprandial Glucose and Nutritional Approaches for Postprandial Glucose Management with a Focus on Whey Proteins

This symposium took place at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden. The first speaker was John L. Sievenpiper, who discussed the pathophysiology of postprandial hyperglycaemia and how it may impact the risk of cardiovascular disease (CVD), peripheral vascular disease, insulin resistance, and other comorbidities in patients with Type 2 diabetes (T2D).

Tropical Diabetic Hand Syndrome: A Case Report and Literature Review

TDHS is characterised by symptoms ranging from a localised cellulitis to gangrene and sepsis. This article reports on the importance of timely intervention and patient education.

Adapting to Telemedicine in Diabetes

THIS year’s European Association for the Study of Diabetes (EASD) Annual Meeting 2022 was a hybrid congress, which focused on inclusion and interaction within the global diabetes community whether participants attended in person in Stockholm, Sweden, or virtually.